Reported Earlier, Merus Announces Publication Of An Abstract On Petosemtamab With Pembrolizumab As 1L Treatment Of r/m HNSCC At 2024 American Society of Clinical Oncology Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Merus announced the publication of an abstract on the combination of Petosemtamab and Pembrolizumab as a first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma. The interim clinical data from 26 patients will be presented at the 2024 ASCO Annual Meeting.
May 24, 2024 | 11:38 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merus has published an abstract on the combination of Petosemtamab and Pembrolizumab for treating recurrent/metastatic head and neck squamous cell carcinoma. The interim data will be presented at the 2024 ASCO Annual Meeting.
The publication of the abstract and the upcoming presentation at a major oncology conference could generate positive sentiment and increased visibility for Merus. This may lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100